# A Randomized Phase 2 Trial of Neoadjuvant Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Patients With Localized Renal Cell Carcinoma.

> **NCT07593040** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Vall d'Hebron Institute of Oncology** · enrollment: 150 (estimated)

## Conditions studied

- Neoadjuvant/Adjuvant Renal Cell Carcinoma

## Interventions

- **DRUG:** Neoadjuvant Pembrolizumab
- **DRUG:** Belzutifan
- **DRUG:** Lenvatinb

## Key facts

- **NCT ID:** NCT07593040
- **Lead sponsor:** Vall d'Hebron Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2028-01
- **Final completion:** 2031-06
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07593040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07593040, "A Randomized Phase 2 Trial of Neoadjuvant Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Patients With Localized Renal Cell Carcinoma.". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT07593040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*